ArticleIntensive care medicine experimental2025
Teicoplanin pharmacokinetics in critically ill patients on extracorporeal organ support: a retrospective analysis.
Article in Intensive care medicine experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Antimicrobial pharmacokinetics and stewardship in critically Ill adult patients receiving ECMO: Challenges, evidence, and future directions.JHLT open · 2026Article
- Therapeutic drug monitoring of daptomycin in a critically ill patient cohort.Frontiers in medicine · 2026Article
- Low isavuconazole trough levels in critically ill patients with and without extracorporeal membrane oxygenation.Antimicrobial agents and chemotherapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtracorporeal membrane oxygenation (ECMO) can alter the pharmacokinetics of diverse antimicrobials, posing challenges in achieving therapeutic drug levels. Some literature suggests that teicoplanin may require higher dosing in ECMO patients, however the respective evidence is scarce. The aim of this study was to assess teicoplanin trough levels in critically patients on ECMO support and to compare patients with and without additional continuous renal replacement therapy (CRRT). We conducted a retrospective study at the Intensive Care Unit (ICU) of the University Hospital Zurich, Switzerland. Teicoplanin trough levels and doses were analyzed in critically ill patients during ECMO support by means of a non-parametric local estimated polynomial regression. Outcomes included the proportion of patients with insufficient or toxic teicoplanin trough levels, dosage adjustments, and differences in teicoplanin trough levels between patients with and without additional CRRT during ECMO support.
resultsAfter screening 172 patients receiving teicoplanin therapy during their ICU stay from 1.1.2020 to 19.07.2023, a total of 23 adult patients were included. The proportion of patients with insufficient teicoplanin levels was notably higher during ECMO support compared to patients with toxic levels (78.3% vs. 13% of patients, respectively). Teicoplanin dosages mostly were increased during the first few days of ECMO treatment. Concomitant CRRT led to a further increase in the proportion of patients with insufficient levels.
conclusionsTeicoplanin trough levels using standard dosing tend to be low in patients on ECMO support, especially in the early days of therapy. Higher doses than the standard regimen are often necessary to achieve therapeutic levels, particularly in patients receiving additional CRRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.